Ocular Therapeutics (NASDAQ:OCUL) has reported positive interim 7-month data for the Phase 1 trial of its implant (OTX-TKI) being developed for wet age-related macular degeneration (Wet AMD) as well as other retinal ailments.
OTX-TKI demonstrated a favorable safety profile, was well tolerated and a detailed presentation of the data is expected on Friday at the American Academy of Ophthalmology (AAO) 2022 annual meeting.
Wet AMD affects about 14 million people worldwide and is a leading cause of blindness.
Read full Disclosure
